MDxHealth Shares Surge 127% as CEO Sees Return to Positive EBITDA
MDXH has more than doubled off its 52-week low of $0.4 on elevated volume (55× avg).
Summary
MDxHealth shares rocketed 127% to $1.04 on Friday after the company reported Q2 revenue of $27.2M, up 16% year-over-year and beating consensus, while reaffirming full-year 2026 sales guidance of $110M-$115M. The stock move is a new trading session event following the Q2 earnings release and $20M registered direct offering disclosed on August 13. CEO Michael McGarrity stated the company expects tissue growth to accelerate in H2, driving a return to positive adjusted EBITDA as it exits 2026. The company also highlighted the GPS PROMPT publication and AI initiatives as support for market share gains ahead of the PROTECT study. This follows the Nasdaq minimum bid and market value deficiency notices from July, making the rebound and guidance reaffirmation a notable positive development for the micro-cap diagnostics firm.
At the time of this announcement, MDXH was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.1M. The 52-week trading range was $0.40 to $5.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.